HIV bone loss mystery: new study probes antiretroviral role
NCT ID NCT00146094
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 25 times
Summary
This study looked at bone loss (osteopenia and osteoporosis) in HIV-infected men. Researchers compared bone density changes over two years between those starting antiretroviral therapy and those not yet on treatment. The goal was to understand if HIV drugs contribute to bone loss. The study was stopped early and included 44 Caucasian men.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier de Colmar
Colmar, 68021, France
-
Centre Hospitalier de Mulhouse
Mulhouse, 68070, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
Conditions
Explore the condition pages connected to this study.